Press Releases

Date Title
Toggle Summary Kura Oncology Expands Protection for Tipifarnib with New U.S. and European Patents
SAN DIEGO , July 11, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced that the U.S. Patent and Trademark Office (USPTO) has issued and the European
Toggle Summary Kura Oncology Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares
SAN DIEGO , June 21, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced the closing of its previously announced underwritten public offering of common stock,
Toggle Summary Kura Oncology Announces Pricing of $100 Million Public Offering of Common Stock
SAN DIEGO , June 18, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced the pricing of an underwritten public offering of 5,900,000 shares of its common stock at a
Toggle Summary Kura Oncology Announces Commencement of Public Offering of Common Stock
SAN DIEGO , June 18, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that it has commenced an underwritten public offering, subject to market and other conditions,
Toggle Summary Kura Oncology Announces Positive Phase 2 Trial of Tipifarnib in Peripheral T-Cell Lymphoma
– Primary endpoint achieved with 45% and 42% ORR in AITL and CXCL12+ AITL/PTCL-NOS expansion cohorts – – PTCL patients with tumors characterized by high CXCL12/CXCR4 expression ratio experienced an ORR of 47% and a clinical benefit rate of 82% – – 50% CR rate and 75% ORR observed in AITL patients
Toggle Summary Kura Oncology to Present at Bank of America Merrill Lynch Health Care Conference
SAN DIEGO , May 08, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that Troy Wilson , Ph.D., J.D., President and Chief Executive Officer, is scheduled to present
Toggle Summary Kura Oncology Reports First Quarter 2019 Financial Results and Highlights Upcoming Milestones
– Registration-directed trial of tipifarnib in HRAS mutant HNSCC continues on track – – Data from ongoing Phase 2 trial of tipifarnib in CXCL12-driven PTCL accepted for oral presentations at EHA and ICML next month – – Data from ongoing Phase 2 trial of tipifarnib in HRAS mutant HNSCC and other
Toggle Summary Kura Oncology to Report First Quarter 2019 Financial Results
SAN DIEGO , April 30, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that it will report first quarter 2019 financial results after the close of U.S.
Toggle Summary Kura Oncology Identifies Farnesylated Proteins Associated with CXCL12 Expression, Potential Biomarker of Clinical Benefit from Tipifarnib in Lymphoma Indications
– Tipifarnib is a farnesyl transferase inhibitor that downregulates CXCL12 – – Gene expression of the exclusively farnesylated RHOE and PRICKLE2 proteins associated with CXCL12 expression – – Pre-treatment tumor CXCL12 expression identified as a potential biomarker of clinical benefit in patients
Toggle Summary Kura Oncology to Participate in Two Upcoming Investor Conferences
SAN DIEGO , March 06, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that Troy Wilson , Ph.D., J.D., President and Chief Executive Officer, is scheduled to